KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Tax Provisions (2016 - 2026)

Pacira BioSciences has reported Tax Provisions over the past 14 years, most recently at $2.1 million for Q1 2026.

  • For Q1 2026, Tax Provisions fell 46.53% year-over-year to $2.1 million; the TTM value through Mar 2026 reached $8.0 million, down 77.5%, while the annual FY2025 figure was $9.8 million, 73.01% down from the prior year.
  • Tax Provisions for Q1 2026 was $2.1 million at Pacira BioSciences, up from -$1.1 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $17.7 million in Q2 2024 and troughed at -$8.0 million in Q4 2022.
  • A 5-year average of $3.9 million and a median of $3.9 million in 2025 define the central range for Tax Provisions.
  • On a YoY basis, Tax Provisions climbed as much as 467.39% in 2023 and fell as far as 1588.84% in 2023.
  • Year by year, Tax Provisions stood at -$8.0 million in 2022, then soared by 211.1% to $8.8 million in 2023, then increased by 7.18% to $9.5 million in 2024, then plummeted by 111.24% to -$1.1 million in 2025, then soared by 295.31% to $2.1 million in 2026.
  • Business Quant data shows Tax Provisions for PCRX at $2.1 million in Q1 2026, -$1.1 million in Q4 2025, and $4.1 million in Q3 2025.